Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week (DDW) meeting.
The company will present the results of two clinical trials that expand the potential health impact of its flagship 24-strain probiotic and prebiotic, DS-01® BOSTON, May 20, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two randomized, double-blind, placebo-controlled clinical trials: one assessing the recovery effects of DS-01® on individuals during and following antibiotic usage, and another evaluating DS-01® in patients with irritable bowel syndrome (IBS). The findings underscore Seed’s mission to transform breakthrough microbiome science into clinically validated consumer health innovations. “DS-01® was formulated to maximize genomic diversity and set an entirely new standard in probiotics,” stated Zain Kassam, M.D., M.P.H, Chief Medical Officer at Seed Health. “Our latest clinical data expands DS-01®'s potential health impact, broadens its clinical use cases, and helps dispel the common perception in the medical community that all probiotics are created equal.” Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, added, “The findings presented at DDW highlight the rigorous biopharma approach we bring to everyday health. We evaluated digestive well-being by studying biopharmaceutical-type biomarkers, exploring possible mechanisms of action in IBS, and conducting deeper microbiome sequencing than typical probiotic trials following antibiotics.” DDW Presentation Highlights
These presentations will detail the methodology and results from the two clinical trials which have important implications for the application of microbiome science in consumer health and well-being. Seed’s Health clinical data on DS-01® Daily Synbiotic for antibiotic recovery and IBS will be presented in the session “Prebiotics, Probiotics and Synbiotics in Health and Disease” on May 20, 2024, from 12:30 PM to 1:30 PM EDT. About Seed Health Media Contact View original content to download multimedia:https://www.prnewswire.com/news-releases/seed-health-to-present-new-clinical-data-on-ds-01-daily-synbiotic-for-both-antibiotic-recovery-and-ibs-at-digestive-disease-week-2024-302149850.html SOURCE Seed Health |